Stay updated on Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page
- Check3 days agoChange DetectedThe site’s footer revision identifier was updated from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check10 days agoChange DetectedThe completed Phase 2 study of imsidolimab for generalized pustular psoriasis is now displayed with its trial details, participant criteria, locations, measured outcomes, and supporting documents, replacing the 403 error page.SummaryDifference48%

- Check17 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check31 days agoChange DetectedA sitewide NIH notice about terminology during the transition from “Artificial Intelligence” to “Super Intelligence” was added, and the site revision changed from v3.7.1 to v3.7.2. The study page continues to display a 403 error.SummaryDifference1%

- Check45 days agoChange DetectedThe site footer’s revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study details and documents with an access-restricted view.SummaryDifference17%

Stay in the know with updates to Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.